Free Trial
NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

NovoCure logo
$11.13 -0.38 (-3.30%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$11.38 +0.24 (+2.20%)
As of 08/8/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NovoCure Stock (NASDAQ:NVCR)

Key Stats

Today's Range
$11.11
$11.69
50-Day Range
$10.97
$18.46
52-Week Range
$10.91
$34.13
Volume
1.37 million shs
Average Volume
2.07 million shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.79
Consensus Rating
Moderate Buy

Company Overview

NovoCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

NVCR MarketRank™: 

NovoCure scored higher than 90% of companies evaluated by MarketBeat, and ranked 105th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NovoCure has only been the subject of 3 research reports in the past 90 days.

  • Read more about NovoCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovoCure is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovoCure is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NovoCure has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.99% of the float of NovoCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NovoCure does not currently pay a dividend.

  • Dividend Growth

    NovoCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.99% of the float of NovoCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NovoCure has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NovoCure this week, compared to 5 articles on an average week.
  • Search Interest

    6 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added NovoCure to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.52% of the stock of NovoCure is held by insiders.

  • Percentage Held by Institutions

    84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NovoCure's insider trading history.
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Stock News Headlines

REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
Wells Fargo Downgrades NovoCure (NVCR)
NovoCure Q2 Revenue Jumps 6 Percent
See More Headlines

NVCR Stock Analysis - Frequently Asked Questions

NovoCure's stock was trading at $29.80 at the beginning of 2025. Since then, NVCR shares have decreased by 62.7% and is now trading at $11.13.

NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, July, 24th. The medical equipment provider reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. The firm's revenue for the quarter was up 5.6% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of NovoCure include Geode Capital Management LLC (2.19%), Connor Clark & Lunn Investment Management Ltd. (0.55%), Emerald Advisers LLC (0.41%) and Emerald Mutual Fund Advisers Trust (0.20%). Insiders that own company stock include Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Asaf Danziger and Mukund Paravasthu.
View institutional ownership trends
.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

Last Earnings
7/24/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NVCR
CIK
1645113
Fax
N/A
Employees
1,488
Year Founded
N/A

Price Target and Rating

High Price Target
$38.00
Low Price Target
$14.50
Potential Upside/Downside
+158.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$168.63 million
Net Margins
-27.13%
Pretax Margin
-22.54%
Return on Equity
-47.74%
Return on Assets
-13.79%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
1.45
Quick Ratio
1.39

Sales & Book Value

Annual Sales
$605.22 million
Price / Sales
2.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
3.56

Miscellaneous

Outstanding Shares
111,800,000
Free Float
105,628,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
0.61

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:NVCR) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners